65,437 trials
HIV
Primary: Proportion of Participants With HIV Viral Load ≥832 Copies/mL (HemaSpot DBS) — 5; 7; 8; 4 Participants — p=.33
Open Angle Glaucoma · Ocular Hypertension
Primary: Intraocular Pressure — -2.30; -2.18 mmHg — p=0.89
Coronary Artery Disease (CAD)
Primary: Sensitivity and Specificity of Flurpiridaz (18F) Injection Positron Emission Tomography (PET) Myocardial Perfusion Imaging (MPI) in the Detection of Significant Coronary…
Peripheral Nerve Discontinuities
Primary: Static Two-Point Discrimination (Pre-defined Mixed Modeling Approach) — 9.1; 9.3 Millimeters
Primary Immunodeficiency Disease
Primary: Rate of Acute Serious Bacterial Infections — 0.015 SBI rate per subject-year
Healthy
Primary: Area Under the Concentration-time Curve of the BI 730357 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 43239.08; 6657.49…
Healthy
Primary: Mass Balance Recovery of Total [14C]-Radioactivity in Urine (Feurine, 0-tz) — 34.3 Percentage of administered dose (%)
Tobacco Smoking
Primary: Number of Participants With Continuous Abstinence at End-of-Treatment (EOT) as Assessed by Self-Report and Bio-verification — 64; 57 Participants
Liver Cancer · Liver Tumor · Hepatocellular Carcinoma
Primary: Changes in Blood Perfusion (Blood Volume)
Healthy Subjects
Primary: Determine the Dose-Response of TSC on tcpO2 Following a Single Administration of TSC in Subjects Breathing O2. — 175.3; 153.1; 178.0; 179.9 mmHg
Nutrient Deficiency · Pregnancy Related
Primary: Change in Maternal Macular Carotenoid Levels From Enrollment to Birth of Infant — 12244; 7343 unitless
Idiopathic Scoliosis
Primary: Unbound Cefazolin Concentration in Skeletal Muscle — 3.22; 5.84 µg/ml/kg
Gallbladder Carcinoma · Metastatic Cholangiocarcinoma · Stage III Intrahepatic Cholangiocarcinoma AJCC v8
Primary: Progression Free Survival (PFS) — 0; 3; 39; 35 Participants — p=0.027
HIV Seropositivity
Primary: Number of Participants in HIV Care (Linkage) Among the Early CCLAD Participants — 31 Participants
Acute Myeloid Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants Who Experienced an Adverse Event (AE) — 3; 6; 4; 6 Participants